Sponsor Dossier
Ferring Pharmaceuticals
Sponsor Dossier for Ferring Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADIN
- Brand: CERVIDIL
- Brand: CORTIMENT
- Brand: DECAPEPTYL
- Brand: DURATOCIN
- Brand: ENDOMETRIN
- Brand: FIRMAGON
- Brand: GLYPRESSIN
- Device (sponsor): Rectal medication/infusion catheter
- Device (sponsor): Syringe, hypodermic, metered-delivery
- Device (sponsor): Euflexxa 1% sodium hyaluronate - Synovial fluid supplementation substance
About
Ferring Pharmaceuticals is an Australian Private Company with ABN 87003037170, registered in New South Wales and currently Active.
Portfolio
Ferring Pharmaceuticals has 15 brands on the ARTG, with 14 indexable brands and 14 brands with Product Information on file. Seven brands are PBS-listed, seven have PBAC outcomes on record, and six have AusPARs on record. Notable brands include ADIN, CERVIDIL, CORTIMENT, DECAPEPTYL, DURATOCIN, ENDOMETRIN, FIRMAGON, GLYPRESSIN, MENOPUR, MINIRIN, NOCDURNA, and OCTOSTIM.
Therapeutic focus
— Women's Health: 5 brands — Endocrinology: 3 brands — Gastroenterology: 3 brands — Immunology: 2 brands — Oncology: 1 brand — Reproductive Health: 1 brand
PBS footprint
Seven brands in the Ferring Pharmaceuticals portfolio are PBS-listed, with the latest PBS schedule date being 2026-05-01.
Regulatory activity
The latest PBAC outcome for Ferring Pharmaceuticals is from 2024-07-01, with seven brands on record having PBAC outcomes. The latest AusPAR is from 2018-03-16, with six brands on record having AusPARs.